Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4458967 | 0.90 | CTSK (0.47) | ITGB3ITGA2BCTSKCYP51A1ACE | |
| SCHEMBL4454262 | 0.90 | ITGB3 (0.42) | ITGB3ITGA2BCTSKCYP51A1ACE | |
| SCHEMBL4452919 | 0.89 | ACE (0.47) | ITGB3ITGA2BACECTSLTSHR | |
| SCHEMBL4450210 | 0.89 | CTSK (0.41) | ITGB3ITGA2BCTSKCYP51A1ACE | |
| SCHEMBL4458898 | 0.88 | ITGB3 (0.41) | ITGB3ITGA2BCTSKCYP51A1ACE | |
| SCHEMBL4449465 | 0.87 | ITGB3 (0.40) | ITGB3ITGA2BCTSKCYP51A1ACE | |
| SCHEMBL4451224 | 0.86 | ITGB3 (0.41) | ITGB3ITGA2BCTSKCYP51A1ACE | |
| SCHEMBL6798801 | 0.86 | ACE (0.43) | ITGB3ITGA2BCTSKACECTSL | |
| SCHEMBL4454188 | 0.85 | ITGB3 (0.40) | ITGB3ITGA2BCYP51A1ACECA1 | |
| SCHEMBL5096314 | 0.84 | HPGDS (0.47) | ITGB3ITGA2BACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1362052-B1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | ITGB3 2837/4885ITGA2B 1887/4885CTSK 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.